Biodel Inc. to Present VIAject Clinical Progress at the 2007 American Diabetes Association Meeting
Company-Sponsored Investor Briefing and Webcast to Follow Presentation DANBURY, Conn., June 20, 2007 /PRNewswire-FirstCall/ -- Biodel Inc. today announced plans to present clinical results of its leading product candidate, VIAject(TM), at the 67th Annual American Diabetes Association (ADA) Scienti...Biodel Corporation - Biodel Inc. Announces VIAject(TM) Phase II Meal ...
Administration of VIAject(TM) resulted in statistically significantly faster ... The data showed that VIAject(TM) provides better postprandial blood glucose ...Biodel Inc. Expands Ongoing Phase III VIAject(TM) Clinical Trials Into ...
Biodel Inc. (Nasdaq: BIOD) announced that the Company has expanded its two ongoing pivotal Phase III clinical trials of VIAject(TM) into Europe. Clinical sites have ...BIOD Biodel to Make New Drug Application for VIAject to FDA
TradingMarkets News for BIOD - Biodel to Make New Drug Application for VIAject to FDA ... VIAject is Biodel's investigational ultra-rapid-acting injectable ...Scott's Web Log: ADA Scientific Sessions: Biodel Announces Regular ...
Specifically, Viaject required less insulin, and the authors also believe that ... Type 1 patients receiving VIAject(TM) showed a 28% reduction in daily prandial ...